The gate that governs sulfotransferase selectivity.

Human cytosolic sulfotransferases (SULTs) transfer the sulfuryl moiety (-SO(3)) from activated sulfate [3'-phosphoadenosine 5'-phosphosulfate (PAPS)] to the hydroxyls and primary amines of numerous metabolites, drugs, and xenobiotics. Receipt of the sulfuryl group often radically alters acceptor-target interactions. How these enzymes select particular substrates from the hundreds of candidates in a complex cytosol remains an important question. Recent work reveals PAPS binding causes SULT2A1 to undergo an isomerization that controls selectivity by constricting the opening through which acceptors must pass to enter the active site. The enzyme maintains an affinity for large substrates by isomerizing between the open and closed states with nucleotide bound. Here, the molecular basis of the nucleotide-induced closure is explored in equilibrium and nonequilibrium molecular dynamics simulations. The simulations predict that the active-site "cap," which covers both the nucleotide and acceptor binding sites, opens and closes in response to nucleotide. The cap subdivides into nucleotide and acceptor halves whose motions, while coupled, exhibit an independence that can explain the isomerization. In silico weakening of electrostatic interactions between the cap and base of the active site causes the acceptor half of the cap to open and close while the nucleotide lid remains shut. Simulations predict that SULT1A1, the most abundant SULT in human liver, will utilize a similar selection mechanism. This prediction is tested using fulvestrant, an anti-estrogen too large to pass through the closed pore, and estradiol, which is not restricted by closure. Equilibrium and pre-steady-state binding studies confirm that SULT1A1 undergoes a nucleotide-induced isomerzation that controls substrate selection.

[1]  C. Falany,et al.  A nucleotide-gated molecular pore selects sulfotransferase substrates. , 2012, Biochemistry.

[2]  M. Suiko,et al.  Sulfation of buprenorphine, pentazocine, and naloxone by human cytosolic sulfotransferases. , 2012, Drug metabolism letters.

[3]  B. Ning,et al.  Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1 , 2011, Pharmacogenomics and personalized medicine.

[4]  R. Zarivach,et al.  The Molecular Basis for the Broad Substrate Specificity of Human Sulfotransferase 1A1 , 2011, PloS one.

[5]  M. Duffel,et al.  Structure-activity relationships for hydroxylated polychlorinated biphenyls as inhibitors of the sulfation of dehydroepiandrosterone catalyzed by human hydroxysteroid sulfotransferase SULT2A1. , 2011, Chemical research in toxicology.

[6]  L. Yin,et al.  Sulfation of 25-hydroxycholesterol by SULT2B1b decreases cellular lipids via the LXR/SREBP-1c signaling pathway in human aortic endothelial cells. , 2011, Atherosclerosis.

[7]  T. Leyh,et al.  The human estrogen sulfotransferase: a half-site reactive enzyme. , 2010, Biochemistry.

[8]  Jackie C Bloomer,et al.  Quantitative Evaluation of the Expression and Activity of Five Major Sulfotransferases (SULTs) in Human Tissues: The SULT “Pie” , 2009, Drug Metabolism and Disposition.

[9]  K. Yoshinari,et al.  Selective Role of Sulfotransferase 2A1 (SULT2A1) in the N-Sulfoconjugation of Quinolone Drugs in Humans , 2009, Drug Metabolism and Disposition.

[10]  Sabbir Ahmed,et al.  Estrone sulfatase and its inhibitors. , 2009, Anti-cancer agents in medicinal chemistry.

[11]  M. Kimura,et al.  Snapshot of a Michaelis complex in a sulfuryl transfer reaction: Crystal structure of a mouse sulfotransferase, mSULT1D1, complexed with donor substrate and accepter substrate. , 2009, Biochemical and biophysical research communications.

[12]  Brian D. Weitzner,et al.  An unusually small dimer interface is observed in all available crystal structures of cytosolic sulfotransferases , 2009, Proteins.

[13]  Simone Florian,et al.  Identification and localization of soluble sulfotransferases in the human gastrointestinal tract. , 2007, The Biochemical journal.

[14]  A. D. Rodrigues,et al.  Pharmacokinetic Drug Interactions Involving 17α-Ethinylestradiol , 2007 .

[15]  A. D. Rodrigues,et al.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. , 2007, Clinical pharmacokinetics.

[16]  Wladek Minor,et al.  HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. , 2006, Acta crystallographica. Section D, Biological crystallography.

[17]  C. Falany,et al.  Pharmacogenetics of human cytosolic sulfotransferases , 2006, Oncogene.

[18]  H. Glatt,et al.  Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue , 2006, International journal of cancer.

[19]  C. Falany,et al.  SULFATION OF RALOXIFENE AND 4-HYDROXYTAMOXIFEN BY HUMAN CYTOSOLIC SULFOTRANSFERASES , 2006, Drug Metabolism and Disposition.

[20]  Jennifer L. Martin,et al.  The Structure of Human SULT1A1 Crystallized with Estradiol , 2005, Journal of Biological Chemistry.

[21]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[22]  Richard D. Taylor,et al.  Modeling water molecules in protein-ligand docking using GOLD. , 2005, Journal of medicinal chemistry.

[23]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[24]  M. Suiko,et al.  Zebrafish tyrosylprotein sulfotransferase: molecular cloning, expression, and functional characterization. , 2004, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[25]  J. Robertson,et al.  Fulvestrant: pharmacokinetics and pharmacology , 2004, British Journal of Cancer.

[26]  Paul Watson,et al.  Virtual Screening Using Protein-Ligand Docking: Avoiding Artificial Enrichment , 2004, J. Chem. Inf. Model..

[27]  D. Häussinger,et al.  Modification of liver cell volume by insulin and glucagon , 1991, Pflügers Archiv.

[28]  M. Zhou,et al.  Crystal structure of human dehydroepiandrosterone sulphotransferase in complex with substrate. , 2002, The Biochemical journal.

[29]  D. G. Walters,et al.  Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[30]  L. Pedersen,et al.  Crystal Structure of the Human Estrogen Sulfotransferase-PAPS Complex EVIDENCE FOR CATALYTIC ROLE OF Ser IN THE SULFURYL TRANSFER REACTION* , 2002 .

[31]  S. Kadota,et al.  Sulfation of environmental estrogens by cytosolic human sulfotransferases. , 2002, Drug metabolism and pharmacokinetics.

[32]  K. Tomer,et al.  The dimerization motif of cytosolic sulfotransferases , 2001, FEBS letters.

[33]  H. Glatt,et al.  Sulfotransferases in the bioactivation of xenobiotics. , 2000, Chemico-biological interactions.

[34]  Junmei Wang,et al.  How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? , 2000, J. Comput. Chem..

[35]  L. Pedersen,et al.  Crystal structure of SULT2A3, human hydroxysteroid sulfotransferase , 2000, FEBS letters.

[36]  C. Parker Dehydroepiandrosterone and dehydroepiandrosterone sulfate production in the human adrenal during development and aging , 1999, Steroids.

[37]  D. Goldstein,et al.  Sources and physiological significance of plasma dopamine sulfate. , 1999, The Journal of clinical endocrinology and metabolism.

[38]  X. Daura,et al.  Peptide Folding: When Simulation Meets Experiment , 1999 .

[39]  C. Falany,et al.  Sulfuryl Transfer: The Catalytic Mechanism of Human Estrogen Sulfotransferase* , 1998, The Journal of Biological Chemistry.

[40]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[41]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[42]  R. Weinshilboum,et al.  Human sulfotransferase SULT1C1: cDNA cloning, tissue-specific expression, and chromosomal localization. , 1997, Genomics.

[43]  C. Falany Enzymology of human cytosolic sulfotransferases , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[45]  C. Falany,et al.  Steroid sulfation by expressed human cytosolic sulfotransferases , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[46]  Wilfred F. van Gunsteren,et al.  The viscosity of SPC and SPC/E water at 277 and 300 K , 1993 .

[47]  H. Wynne,et al.  The association of age with the activity of alcohol dehydrogenase in human liver. , 1992, Age and ageing.

[48]  Kenneth A. Johnson,et al.  1 Transient-State Kinetic Analysis of Enzyme Reaction Pathways , 1992 .

[49]  H. Berendsen,et al.  Transport Properties Computed by Linear Response through Weak Coupling to a Bath , 1991 .

[50]  C. Falany,et al.  Purification and characterization of human liver phenol-sulfating phenol sulfotransferase. , 1990, Archives of biochemistry and biophysics.

[51]  H. Berendsen,et al.  A LEAP-FROG ALGORITHM FOR STOCHASTIC DYNAMICS , 1988 .

[52]  L. Pearce,et al.  Purification and kinetic characterization of a phenol-sulfating form of phenol sulfotransferase from human brain. , 1986, Archives of biochemistry and biophysics.

[53]  T. Okanoue,et al.  Relationship of Mallory bodies to intermediate filaments in hepatocytes. A scanning electron microscopy study. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[54]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[55]  R. Weinshilboum,et al.  Acetaminophen and phenol: substrates for both a thermostable and a thermolabile form of human platelet phenol sulfotransferase. , 1982, The Journal of pharmacology and experimental therapeutics.

[56]  C. Goresky,et al.  A linear method for determining liver sinusoidal and extravascular volumes. , 1963, The American journal of physiology.